Amended Current Report Filing (8-k/a)
June 05 2023 - 4:51PM
Edgar (US Regulatory)
0001870144
true
Amendment No 1
0001870144
2023-03-08
2023-03-08
0001870144
CDIO:CommonStockParValue0.00001Member
2023-03-08
2023-03-08
0001870144
CDIO:RedeemableWarrantsEachWarrantExercisableForOnehalfOfOneShareOfCommonStockMember
2023-03-08
2023-03-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
(Amendment No. 1)
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March
8, 2023
Date of Report (Date of earliest event reported)
CARDIO DIAGNOSTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-41097 |
|
87-0925574 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
400 North Aberdeen Street, Suite 900, Chicago, IL |
|
60642 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (631) 796-5412
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.00001 |
|
CDIO |
|
The Nasdaq Stock Market LLC |
Redeemable warrants, each warrant exercisable for one-half of one share of common stock |
|
CDIOW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Explanatory Note
This Form 8-K/A is being
filed as an amendment to the Current Report on Form 8-K filed with the Securities and Exchange Commission by Cardio Diagnostics Holdings,
Inc. on March 13, 2023 (the “Original 8-K”).
Item 1.01 |
Entry into a Material Definitive Agreement. |
On March 8, 2023, the Company entered into a
securities purchase agreement (the “Securities Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”), a fund
managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. Pursuant to the Securities Purchase Agreement, the
Company agreed to issue and sell to Yorkville convertible debentures (the “Convertible Debentures”) in the principal amount
of up to $11.2 million, which are convertible into shares of the Company’s Common Stock, $0.00001 par value (as converted, the “Conversion
Shares”) on the terms and subject to the conditions set forth therein. As previously reported, on March 8, 2023, upon signing the
Securities Purchase Agreement, the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5.0 million
for a purchase price of $4.5 million (the “First Convertible Debenture”). Pursuant to the Securities Purchase Agreement, the
parties further agreed that the Company will issue and sell to Yorkville, and Yorkville will purchase from the Company, a second Convertible
Debenture in the principal amount of $6.2 million for a purchase price of $5.58 million upon satisfaction or waiver of certain specified
conditions (the “Second Closing”).
The
Amendment
By letter agreement
dated June 2, 2023 (the “Amendment”), the Company and Yorkville mutually agreed that the date of the Second Closing will be
September 15, 2023 (or such other date that is mutually agreed upon by the Company and Yorkville), provided that as of such date, the
conditions to the Second Closing as set forth in Sections 6 and 7 of the Securities Purchase Agreement have been satisfied or waived.
Attached to the Amendment is the form of Closing Statement, the form of Convertible Debenture for the Second Closing and the Compliance
Certificate, the executed versions of which will be delivered by the Company to Yorkville at the Second Closing.
Except as set forth
above, this Amendment does not modify or update the disclosures presented in, or exhibits to, the
Original Filing in any way. The disclosures presented therein, as modified by the Amendment, are hereby incorporated by reference into
this Item 1.01.
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The information set forth in Item 2.03 of the
Original 8-K and Item 1.01 of this Amendment are hereby incorporated by reference into this Item 2.03 in its entirety.
Item 3.02 |
Unregistered Sales of Equity Securities. |
The information set forth in Item 3.02 of the
Original 8-K and Item 1.01 of this Amendment are hereby incorporated by reference into this Item 3.02 in its entirety.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 5, 2023 |
CARDIO DIAGNOSTICS HOLDINGS INC. |
|
|
|
By: |
/s/ Elisa Luqman |
|
|
Elisa Luqman Chief Financial Officer |
Mana Capital Acquisition (NASDAQ:MAAQU)
Historical Stock Chart
From Oct 2024 to Nov 2024
Mana Capital Acquisition (NASDAQ:MAAQU)
Historical Stock Chart
From Nov 2023 to Nov 2024